BICILLIN L-A (penicillin g benzathine) by Thayer Medical is mechanism of action penicillin g exerts a bactericidal action against penicillin-susceptible microorganisms during the stage of active multiplication. Approved for the treatment of infections due to penicillin-g-sensitive microorganisms, very prolonged serum levels common to this particular dosage form. First approved in 1958.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
BICILLIN L-A is a long-acting penicillin G benzathine injectable antibiotic approved in 1958 for treatment of penicillin-susceptible bacterial infections. It works by inhibiting bacterial cell-wall peptidoglycan synthesis, achieving bactericidal activity during active microbial multiplication. The formulation is notable for producing very prolonged serum levels, enabling extended dosing intervals.
Product is approaching loss of exclusivity with modest Part D spending ($4M), indicating a mature legacy franchise with limited growth opportunities and likely small dedicated team.
Mechanism of Action Penicillin G exerts a bactericidal action against penicillin-susceptible microorganisms during the stage of active multiplication. It acts through the inhibition of biosynthesis of cell-wall peptidoglycan, rendering the cell wall osmotically unstable.
Worked on BICILLIN L-A at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moBICILLIN L-A represents a legacy mature product with minimal current job market activity and declining career development opportunities. Career professionals should anticipate this as a maintenance-mode asset with limited growth trajectory, suited for specialists in supply chain, compliance, or generic/branded transition management rather than innovation-focused roles.